Navigation Links
Advanced Life Sciences Announces Second Quarter 2009 Financial Results and Financial Outlook
Date:8/11/2009

CHICAGO, Aug. 11 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced its financial results for the second quarter ended June 30, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)

The net loss allocable to common shareholders for the three months ended June 30, 2009 was $2.6 million or ($0.06) per share compared to a net loss allocable to common shareholders of $3.4 million or ($0.09) per share for the three months ended June 30, 2008. The decrease in the net loss is due to decreased costs involved in the clinical development of the Company's lead compound, Restanza(TM) (cethromycin).

The Company ended the second quarter of 2009 with cash and cash equivalents totaling $1.0 million. Cash used during the quarter was approximately $2.9 million.

"Advanced Life Sciences today is focused on continuing to pursue approval for Restanza in community acquired pneumonia or CAP and complying with the recommendations by the FDA concerning next steps that can lead to a registration pathway," said Michael T. Flavin, Ph.D., chairman and chief executive officer of Advanced Life Sciences. "Based on the agency's recent communication with the Company, we anticipate that an additional well-controlled clinical study designed to demonstrate efficacy in a more severe CAP population will likely be required for the approval of Restanza. We intend to work closely with the agency to design and establish a protocol under a Special Protocol Assessment. We are working on these clinical plans with Wyeth, our development and commercialization partner in the Asia
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels
2. Advanced Life Sciences to Host 2009 Second Quarter Financial Results Conference Call and Webcast
3. Next Safety Releases Advanced Respirator for Infectious Diseases
4. Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia
5. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
6. Enerkem Announces World-Class Advanced Energy Research Center in Edmonton, Alberta, Canada
7. Unexpectedly long-range effects in advanced magnetic devices
8. UCF teams advanced nerve cell system could help cure diabetic neuropathy, related diseases
9. Advanced Life Sciences Restanza(TM) Shows 100% Survival In Confirmatory Anthrax Study
10. Visage Imaging to Provide Visage(R) CS Enterprise Wide Advanced Visualization Solutions to Advanced Radiology Consultants
11. Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic Assays
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... MESSENGER has just celebrated its 10 year anniversary in ... of its latch valves, V27200-818, operating onboard this spacecraft. ... the planet Mercury. It is only the second spacecraft ... vast amount of information and images of the planet. ... that also include permanent magnets to maintain the valve ...
(Date:9/16/2014)... September 16, 2014 “Nature has developed, ... features that we desire in optical design,” said Joseph ... State University. “As we explore surfaces and structures at ... lessons were presented in San Diego in August during ... in Nature ” chaired by Shaw and Rongguang Liang ...
(Date:9/16/2014)... SAN DIEGO , Sept. 16, 2014  Biocom, ... life science community, recognizes the 9 th ... to the value of IT technologies in improving our ... California is one of the world,s most ... from EHRs to mobile health applications to genomic testing ...
(Date:9/16/2014)... a deicing film for radar domes have now refined ... glass. , The new work by Rice chemist ... from windshields to skyscrapers free of ice and fog ... , The technology was introduced this month in the ... . , The material is made of graphene ...
Breaking Biology Technology:Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5Biocom Recognizes National Health IT Week 2Nanoribbon film keeps glass ice-free 2
... Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") ... has dosed the first patient in its Phase ... University of California, San Diego ("UCSD"), ... Cysteamine") capsules in nephropathic cystinosis ("cystinosis"), a rare ...
... Interim Primary Endpoint Data from Phase II Study Shows 71% ... Docetaxel - , , - Secondary Endpoint Evaluation Shows ... Cohort - , , ORLANDO, Fla. and TUSTIN, Calif., ... ) today announced that preliminary results from a Phase II ...
... Clinical Oncology , , ORLANDO, Fla., June 1 ... use of ChemoFX(R), a chemosensitivity assay, to predict the ... of individual patients. Results from the study show ... percent were responsive to cetuximab, a result that is ...
Cached Biology Technology:Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 2Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 3Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 4Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 5Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 2Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 3Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 4Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 5Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 6Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 2Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 3
(Date:9/16/2014)... Philadelphia, PA, September 16, 2014 Schizophrenia is associated ... A growing body of research suggests that the relationship ... effort by patients to use nicotine to self-medicate symptoms ... new study, published in the current issue of ... authors found that the level of nicotine receptors in ...
(Date:9/16/2014)... the Exxon Valdez spilled 11 million gallons of oil ... up another giant oil spill in the Gulf of ... the Journal of Consumer Research , news coverage ... instead of catalyzing changes in the way fossil fuels ... media coverage of these two events helped to resolve ...
(Date:9/16/2014)... -- As open enrollment season approaches, U.S. employees will soon ... benefits. According to Aon Hewitt , the global ... plc (NYSE: AON ), employees will ... managing their health care decisions. This increased responsibility makes ... how they can make the most of the programs ...
Breaking Biology News(10 mins):Smoking and schizophrenia linked by alterations in brain nicotine signals 2Exxon Valdez 2014: Does media coverage of manmade disasters contribute to consumer complacency? 2Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 2Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 3Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 4Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 5Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 6Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 7
... "crack baby" hysteria of the 1980s was greatly ... but disabling cognitive impairments -- attention deficits, learning ... study by investigators at the Vanderbilt Kennedy Center ... the long-term behavioral and neurological problems associated with ...
... especially those that are hydrophobic or water-repellant, to tumors ... develop innovative delivery systems that keep these drugs intact ... University at Buffalo’s Institute for Lasers, Photonics and Biophotonics ... solution in which the delivery system is the drug ...
... Researchers have linked a structural protein called nestin to ... new biomarker that could lead to earlier detection and ... of Cancer Research, researchers from Dartmouth Medical School demonstrate ... basal epithelial breast tumors, a highly aggressive cancer with ...
Cached Biology News:Prenatal cocaine's lasting cellular effects 2Prenatal cocaine's lasting cellular effects 3No carrier necessary: This drug delivers itself 2Selective marker found to indicate aggressive form of breast cancer 2
... The Neural Stem Cell Expansion Kit - ... in vitro NSC expansion as a monolayer ... specially formulated N-2 Plus Media Supplement, which has ... K.K. et al . (1996) Genes & ...
... RNase-Free DNase is a preparation of ... double-stranded DNA to produce 3-hydroxyl oligonucleotides. ... in applications where maintaining the integrity ... is qualified for use with the ...
... Fragment is a genetically engineered Klenow polymerase in ... been removed, leaving only the 5 to 3 ... Exo- Klenow Fragment the enzyme of choice for ... the random primed method, and for DNA sequencing ...
... RNA polymerase is a DNA-dependent RNA polymerase ... promoters. It efficiently synthesizes in vitro ... down stream from a T7 promoter. ... templates for in vitro translation, substrates in ...
Biology Products: